The FDA approved trifluridine and tipiracil (LONSURF, Taiho Oncology) with bevacizumab, for metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor biological therapy, and if RAS wild-type, an anti-epidermal growth factor receptor therapy. The FDA had previously approved single-agent LONSURF for this indication in September 2015.
Safety and efficacy were evaluated in SUNLIGHT, an